Surveyor Capital invests in VectivBio

On 15 October 2020, VectivBio AG, a Basel-based clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, announced the closing of its USD 110 million crossover financing from new investors, among which Surveyor Capital, a Citadel company, with the participation of existing investors.

Lenz & Staehelin advised Surveyor Capital on the Swiss aspects of this transaction.  Choate, Hall & Stewart LLP acted as international counsel to Surveyor Capital.